By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that Aetna has determined that the firm's AlloMap test is medically necessary for monitoring rejection in heart transplant recipients more than a year after a heart transplant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.